LIAN - Bristol Myers LianBio's heart drug Camzyos meets main goal in Chinese patients study

2023-04-26 08:53:02 ET

• Bristol Myers Squibb ( NYSE: BMY ) and LianBio's ( NASDAQ: LIAN ) drug Camzyos (mavacamten) met the main goal of a phase 3 trial in Chinese patients with a type of heart disease.
• LianBio was evaluating mavacamten in the study, dubbed EXPLORER-CN, to treat Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
• HCM is a condition in which the heart muscle becomes abnormally thick which can make it harder for the heart to pump blood.
• The trial met its main goal, showing a statistically significant and clinically meaningful improvement in Valsalva left ventricular outflow tract (LVOT) gradient from the time treatment started to week 30, compared to placebo.
• In addition, mavacamten showed improvement for all secondary goals, the company added.
• The drug showed a safety profile consistent with previous studies.
• Camzyos is currently under priority review in China and the filing was backed by data from a global phase 3 trial called EXPLORER-HCM and phase 1 pharmacokinetic study in healthy Chinese people.
• "With positive pivotal data now in hand and the NDA on file, we are optimistic about bringing mavacamten to market in China next year," said LianBio CEO Yizhe Wang.
• The U.S. FDA is expected to make a decision by June 16 on an expanded use of the drug based on data from a phase 3 trial called VALOR-HCM.
• LIAN +1.04% to $1.95 premarket April 26

For further details see: